NCT00677313

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 5 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label study to provide metreleptin for the treatment of diabetes mellitus and/or hypertriglyceridemia associated with lipodystrophy. This study intends to provide guidance to investigators with respect to identification of appropriate subjects for metreleptin treatment, guidance on metreleptin dosing, and collection of safety and efficacy data following metreleptin treatment in this population

Conditions

• Lipodystrophy

Interventions

Type	Name	Description
DRUG	metreleptin	metreleptin injection

Timeline

• Start date: 2009-03-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2008-05-14
• Last updated: 2015-04-30

Locations

5 sites across 1 country: United States